Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modeling the microplastic distribution along the Delaware River Estuary: Accumulation patterns and hydrodynamic influences.

Marine pollution bulletin·2025
Same author

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort.

Arthritis research & therapy·2025
Same author

Preventive effects of early immunosuppressive treatment on the development of interstitial lung disease in systemic sclerosis.

Rheumatology (Oxford, England)·2024
Same author

Quantifying the influence of size, shape, and density of microplastics on their transport modes: A modeling approach.

Marine pollution bulletin·2024
Same author

Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review.

European journal of internal medicine·2024
Same author

Low back pain patients with Modic type 1 changes exhibit distinct bacterial and non-bacterial subtypes.

Osteoarthritis and cartilage open·2024
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

[Systemic sclerosis. Objectives for the treatment].

B Maurer1, M Walder, R E Gay

  • 1Zentrum für Experimentelle Rheumatologie und Zentrum für Integrative Humanphysiologie, Zürich, Schweiz.

Zeitschrift Fur Rheumatologie
|January 16, 2009
PubMed
Summary
This summary is machine-generated.

Systemic sclerosis (SSc) is a fibrotic disorder lacking specific treatments. New therapeutic strategies targeting key fibrogenesis and vasculopathy molecules are needed to improve patient outcomes.

Related Experiment Videos

Last Updated: Jun 26, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Rheumatology
  • Immunology
  • Fibrotic Diseases

Background:

  • Systemic sclerosis (SSc) is a severe multi-systemic fibrotic disorder characterized by vasculopathy, inflammation, autoimmunity, and fibrosis.
  • While management of organ complications has improved outcomes, no approved therapy halts disease progression.
  • Conventional disease-modifying antirheumatic drugs (DMARDs) have shown limited impact on SSc course and survival.

Purpose of the Study:

  • To discuss current and future therapeutic concepts for Systemic Sclerosis.
  • To redefine treatment objectives based on identified molecular pathomechanisms.
  • To evaluate diagnostic tools for pulmonary arterial hypertension, lung fibrosis, and skin/systemic fibrosis in SSc.

Main Methods:

  • Review of recent studies on molecular pathomechanisms in SSc.
  • Analysis of findings from various animal models of SSc.
  • Discussion of current therapeutic strategies and diagnostic tools.

Main Results:

  • Identification of key molecules involved in fibrogenesis and vasculopathy in SSc.
  • Recognition of the need to reconsider and redefine treatment objectives.
  • Emphasis on improved management of organ complications contributing to better clinical outcomes.

Conclusions:

  • Current treatment strategies for SSc require re-evaluation based on molecular insights.
  • Future therapeutic approaches should target identified key molecules to slow disease progression.
  • Development of novel diagnostic tools is crucial for managing SSc-related complications like pulmonary arterial hypertension and fibrosis.